References
- Australian Institute of Health and Welfare. Dementia in Australia: National data analysis and development. AIHW cat. no. AGE 53. Canberra: AIHW; 2006.
- Access Economics. Dementia estimates and projections: Australian states and territories. Report for Alzheimer's Australia. Canberra: Access Economict Limited, February; 2005.
- Australian Institute of Health and Welfare. Dementia in Australia: national data analysis and development. Canberra: AIHW; 2007.
- Birks J, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer’s disease (Cochrane Review). The Cochrane Library; 2001; 1. Oxford.
- Birks J, Grimley Evans J, Iakovodou V, Tsolaki M. Rivastigmine for Alzheimer’s disease (Cochrane Review). The Cochrane Library; 2001; 1. Oxford.
- Kaduszkiewicz H, Zimmemann T, Bornholdt H, Bussche H. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ Aug 2005; 331:321–327.
- Neurology Writing Group. Therapeutic guidelines: neurology, version 2. Melbourne: Therapeutic Guidelines Ltd; 2002.
- Qaseem A, Snow V, Cross J . Current pharmacological treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008; 148:370–378.
- Department of Health and Ageing. PBS for health professionals. Canberra: Department of Health and Ageing; 2008.
- National Prescribing Service Newsletter 59. Drugs used in dementia in the elderly. Sydney: National Prescribing Service Limited; August; 2008.
- National Prescribing Service Newsletter 16. New Alzheimer 's drugs show only modest benefits. Sydney: National Prescribing Service Limited; June 2001.
- Woodward M, Byrne G, Brodatv H, Graham M. Treatment cessation rates in patients with Alzheimer's disease being treated with acetylcholinesterase inhibitors: an Australian disease cohort analysis. Intern Med J 2006; 36:A164.
- Suh D, Thomas S, Valiyeva E, Arcona S, Vo L. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs Aging 2005; 22:695–707.
- Roe C, Anderson M, Spivack B. How many patients complete an adequate trial of donepezil? Alzheimer Dis Assoc Disord 2002; 16:49–51.
- IMS Consulting. Australia's centralized cost-effectiveness requirement for pharmaceuticals: potential implications for US patients. London: IMS World Publications; 2006.
- Lloyd J, Anderson P. Veterans' use of health services. Aged care series no.13. Cat. no. AGE 51. Canberra: Australian Institute of Health and Welfare; 2008.